

Ram I Mahato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8898633/publications.pdf>

Version: 2024-02-01

159
papers

9,036
citations

31976

53
h-index

51608

86
g-index

163
all docs

163
docs citations

163
times ranked

9974
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of magnesium stearate surface coating method on the aerosol performance and permeability of micronized fluticasone propionate. <i>International Journal of Pharmaceutics</i> , 2022, 615, 121470.	5.2	4
2	Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia. <i>Journal of Geriatric Oncology</i> , 2022, 13, 871-874.	1.0	9
3	Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer. <i>Journal of Controlled Release</i> , 2021, 329, 585-597.	9.9	5
4	Activation of dsRNA-Dependent Protein Kinase R by MicroRNA-378 Sustains Metabolic Inflammation in Hepatic Insulin Resistance. <i>Diabetes</i> , 2021, , db200181.	0.6	5
5	Opportunities and challenges of fatty acid conjugated therapeutics. <i>Chemistry and Physics of Lipids</i> , 2021, 236, 105053.	3.2	14
6	Effect of geriatric assessment (GA) and genetic profiling on overall survival (OS) of older adults with acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7021-7021.	1.6	1
7	Lipid based nanocarriers for effective drug delivery and treatment of diabetes associated liver fibrosis. <i>Advanced Drug Delivery Reviews</i> , 2021, 173, 394-415.	13.7	25
8	2,2-Bis(hydroxymethyl) propionic acid based cyclic carbonate monomers and their (co)polymers as advanced materials for biomedical applications. <i>Biomaterials</i> , 2021, 275, 120953.	11.4	12
9	Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma. <i>Biomaterials</i> , 2021, 278, 121138.	11.4	14
10	Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113888.	13.7	62
11	Diabetes associated fibrosis and drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113968.	13.7	2
12	Activation of dsRNA-Dependent Protein Kinase R by miR-378 Sustains Metabolic Inflammation in Hepatic Insulin Resistance. <i>Diabetes</i> , 2021, 70, 710-719.	0.6	11
13	Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy. <i>Science Advances</i> , 2020, 6, .	10.3	42
14	ApoE mimetic peptide targeted nanoparticles carrying a BRD4 inhibitor for treating Medulloblastoma in mice. <i>Journal of Controlled Release</i> , 2020, 323, 463-474.	9.9	30
15	Functional similarity of modified cascade impactor to deposit drug particles on cells. <i>International Journal of Pharmaceutics</i> , 2020, 583, 119404.	5.2	5
16	Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment. <i>Advanced Therapeutics</i> , 2020, 3, 1900136.	3.2	23
17	Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment. <i>Journal of Controlled Release</i> , 2019, 309, 231-243.	9.9	15
18	The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis. <i>Theranostics</i> , 2019, 9, 7537-7555.	10.0	17

#	ARTICLE	IF	CITATIONS
19	Polymeric Micellar Delivery of Novel Microtubule Destabilizer and Hedgehog Signaling Inhibitor for Treating Chemoresistant Prostate Cancer. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 864-875.	2.5	10
20	ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 14647-14659.	8.0	49
21	Roles of microRNAs in T cell immunity: Implications for strategy development against infectious diseases. <i>Medicinal Research Reviews</i> , 2019, 39, 706-732.	10.5	16
22	Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy. <i>Materials Today</i> , 2019, 25, 66-87.	14.2	22
23	Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer. <i>Biomaterials</i> , 2019, 192, 95-108.	11.4	52
24	Design of Hedgehog pathway inhibitors for cancer treatment. <i>Medicinal Research Reviews</i> , 2019, 39, 1137-1204.	10.5	33
25	Self-assembling lisofylline-fatty acid conjugate for effective treatment of diabetes mellitus. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 15, 175-187.	3.3	13
26	Coadministration of Polymeric Conjugates of Docetaxel and Cyclopamine Synergistically Inhibits Orthotopic Pancreatic Cancer Growth and Metastasis. <i>Pharmaceutical Research</i> , 2018, 35, 17.	3.5	10
27	MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis. <i>Advanced Drug Delivery Reviews</i> , 2018, 129, 54-63.	13.7	98
28	Lipid-polymer hybrid nanocarriers for delivering cancer therapeutics. <i>Journal of Controlled Release</i> , 2018, 271, 60-73.	9.9	103
29	Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis. <i>Molecular Therapy</i> , 2018, 26, 2798-2811.	8.2	21
30	Co-delivery of siAlox15 and sunitinib for reversing the new-onset of type 1 diabetes in non-obese diabetic mice. <i>Journal of Controlled Release</i> , 2018, 292, 1-12.	9.9	11
31	Cholesterol and Morpholine Grafted Cationic Amphiphilic Copolymers for miRNA-34a Delivery. <i>Molecular Pharmaceutics</i> , 2018, 15, 2391-2402.	4.6	30
32	Impact of miRNA-mRNA Profiling and Their Correlation on Medulloblastoma Tumorigenesis. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 12, 490-503.	5.1	36
33	Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice. <i>Theranostics</i> , 2018, 8, 4033-4049.	10.0	35
34	Polymer conjugate of a microtubule destabilizer inhibits lung metastatic melanoma. <i>Journal of Controlled Release</i> , 2017, 249, 32-41.	9.9	9
35	Recent advances in hepatocellular carcinoma therapy. , 2017, 173, 106-117.		216
36	Nanomedicines for the Treatment of CNS Diseases. <i>Journal of NeuroImmune Pharmacology</i> , 2017, 12, 1-5.	4.1	38

#	ARTICLE	IF	CITATIONS
37	Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 3244-3254.	0.9	60
38	Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer. <i>Scientific Reports</i> , 2017, 7, 1665.	3.3	31
39	Bioconjugate Therapeutics: Current Progress and Future Perspective. <i>Molecular Pharmaceutics</i> , 2017, 14, 1321-1324.	4.6	28
40	Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. <i>Cancer Letters</i> , 2017, 402, 1-8.	7.2	88
41	Pharmacokinetics and Biodistribution of GDC-0449 Loaded Micelles in Normal and Liver Fibrotic Mice. <i>Pharmaceutical Research</i> , 2017, 34, 564-578.	3.5	16
42	Challenges and Recent Advances in Medulloblastoma Therapy. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 1061-1084.	8.7	66
43	EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer. <i>Molecular Pharmaceutics</i> , 2017, 14, 3121-3133.	4.6	43
44	Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. <i>Molecular Pharmaceutics</i> , 2017, 14, 1365-1372.	4.6	25
45	Combination therapy of paclitaxel and cyclophosphamide polymer-drug conjugates to treat advanced prostate cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 391-401.	3.3	56
46	Mesenchymal stem cell and derived exosome as small RNA carrier and Immunomodulator to improve islet transplantation. <i>Journal of Controlled Release</i> , 2016, 238, 166-175.	9.9	140
47	EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer. <i>Biomacromolecules</i> , 2016, 17, 301-313.	5.4	41
48	Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer. <i>Molecular Pharmaceutics</i> , 2016, 13, 1822-1832.	4.6	21
49	Co-delivery of small molecule hedgehog inhibitor and miRNA for treating liver fibrosis. <i>Biomaterials</i> , 2016, 76, 144-156.	11.4	60
50	Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 267-275.	2.4	19
51	Synthesis and Characterization of a Novel Mycophenolic Acid-Quinic Acid Conjugate Serving as Immunosuppressant with Decreased Toxicity. <i>Molecular Pharmaceutics</i> , 2015, 12, 4445-4453.	4.6	7
52	Codelivery of Small Molecule Hedgehog Inhibitor and miRNA for Treating Pancreatic Cancer. <i>Molecular Pharmaceutics</i> , 2015, 12, 1289-1298.	4.6	74
53	Small molecules targeting microRNA for cancer therapy: Promises and obstacles. <i>Journal of Controlled Release</i> , 2015, 219, 237-247.	9.9	80
54	Systemic delivery of nanoparticle formulation of novel tubulin inhibitor for treating metastatic melanoma. <i>Drug Delivery and Translational Research</i> , 2015, 5, 199-208.	5.8	13

#	ARTICLE	IF	CITATIONS
55	Micellar formulation of indocyanine green for phototherapy of melanoma. <i>Journal of Controlled Release</i> , 2015, 220, 130-140.	9.9	49
56	Nanoparticle-mediated drug delivery for treating melanoma. <i>Nanomedicine</i> , 2015, 10, 2613-2633.	3.3	46
57	Delivery and Targeting of miRNAs for Treating Liver Fibrosis. <i>Pharmaceutical Research</i> , 2015, 32, 341-361.	3.5	43
58	miRNAs as targets for cancer treatment: Therapeutics design and delivery. <i>Advanced Drug Delivery Reviews</i> , 2015, 81, v-vi.	13.7	11
59	miRNAs in pancreatic cancer: Therapeutic potential, delivery challenges and strategies. <i>Advanced Drug Delivery Reviews</i> , 2015, 81, 34-52.	13.7	77
60	Design of nanocarriers for efficient cellular uptake and endosomal release of small molecule and nucleic acid drugs: learning from virus. <i>Frontiers of Chemical Science and Engineering</i> , 2014, 8, 387-404.	4.4	17
61	Core-shell nanoparticulate formulation of gemcitabine: lyophilization, stability studies, and in vivo evaluation. <i>Drug Delivery and Translational Research</i> , 2014, 4, 439-451.	5.8	7
62	Nanomedicines of Hedgehog Inhibitor and PPAR- β Agonist for Treating Liver Fibrosis. <i>Pharmaceutical Research</i> , 2014, 31, 1158-1169.	3.5	41
63	Doxorubicin and Lapatinib Combination Nanomedicine for Treating Resistant Breast Cancer. <i>Molecular Pharmaceutics</i> , 2014, 11, 2600-2611.	4.6	72
64	MicroRNAs and Drug Resistance in Prostate Cancers. <i>Molecular Pharmaceutics</i> , 2014, 11, 2539-2552.	4.6	63
65	A Preface for Engineered Biomimetic Tissue Platforms for in Vitro Drug Evaluation. <i>Molecular Pharmaceutics</i> , 2014, 11, 1931-1932.	4.6	0
66	LHRH-Conjugated Micelles for Targeted Delivery of Antiandrogen to Treat Advanced Prostate Cancer. <i>Pharmaceutical Research</i> , 2014, 31, 2784-2795.	3.5	17
67	Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. <i>Biomaterials</i> , 2014, 35, 7077-7087.	11.4	137
68	Mesenchymal stem cell-based therapy for type 1 diabetes. <i>Discovery Medicine</i> , 2014, 17, 139-43.	0.5	45
69	Mesenchymal Stem Cell-Based Therapy. <i>Molecular Pharmaceutics</i> , 2013, 10, 77-89.	4.6	101
70	Effect of PEGylation on Biodistribution and Gene Silencing of siRNA/Lipid Nanoparticle Complexes. <i>Pharmaceutical Research</i> , 2013, 30, 342-351.	3.5	81
71	Lactic acid- and carbonate- based crosslinked polymeric micelles for drug delivery. <i>Journal of Polymer Science Part A</i> , 2013, 51, 347-362.	2.3	24
72	miRNA profiling in pancreatic cancer and restoration of chemosensitivity. <i>Cancer Letters</i> , 2013, 334, 211-220.	7.2	83

#	ARTICLE	IF	CITATIONS
73	Third-party Mesenchymal Stem Cells Improved Human Islet Transplantation in a Humanized Diabetic Mouse Model. <i>Molecular Therapy</i> , 2013, 21, 1778-1786.	8.2	45
74	Self-Assembling, Amphiphilic Polymer-Gemcitabine Conjugate Shows Enhanced Antitumor Efficacy Against Human Pancreatic Adenocarcinoma. <i>Bioconjugate Chemistry</i> , 2013, 24, 1161-1173.	3.6	84
75	Synthesis and Characterization of an Anti-Apoptotic Immunosuppressive Compound for Improving the Outcome of Islet Transplantation. <i>Bioconjugate Chemistry</i> , 2013, 24, 2036-2044.	3.6	7
76	Genetically Modified Human Bone Marrow Derived Mesenchymal Stem Cells for Improving the Outcome of Human Islet Transplantation. <i>PLoS ONE</i> , 2013, 8, e77591.	2.5	14
77	Formulation and Characterization of Polyester/Polycarbonate Nanoparticles for Delivery of a Novel Microtubule Destabilizing Agent. <i>Pharmaceutical Research</i> , 2012, 29, 3064-3074.	3.5	18
78	Attenuation of early liver fibrosis by pharmacological inhibition of smoothened receptor signaling. <i>Journal of Drug Targeting</i> , 2012, 20, 770-782.	4.4	38
79	Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment. <i>Expert Opinion on Drug Delivery</i> , 2012, 9, 1443-1447.	5.0	12
80	Chemoresistance in Prostate Cancer Cells Is Regulated by miRNAs and Hedgehog Pathway. <i>PLoS ONE</i> , 2012, 7, e40021.	2.5	99
81	Micellar Delivery of Cyclopamine and Gefitinib for Treating Pancreatic Cancer. <i>Molecular Pharmaceutics</i> , 2012, 9, 2350-2357.	4.6	47
82	Combination Therapy of Antiandrogen and XIAP Inhibitor for Treating Advanced Prostate Cancer. <i>Pharmaceutical Research</i> , 2012, 29, 2079-2091.	3.5	30
83	Cyclopamine Attenuates Acute Warm Ischemia Reperfusion Injury in Cholestatic Rat Liver: Hope for Marginal Livers. <i>Molecular Pharmaceutics</i> , 2011, 8, 958-968.	4.6	33
84	Combining Stem Cells and Genes for Effective Therapeutics. <i>Molecular Pharmaceutics</i> , 2011, 8, 1443-1445.	4.6	0
85	Targeted TFO delivery to hepatic stellate cells. <i>Journal of Controlled Release</i> , 2011, 155, 326-330.	9.9	23
86	Genetically Modified Mesenchymal Stem Cells for Improved Islet Transplantation. <i>Molecular Pharmaceutics</i> , 2011, 8, 1458-1470.	4.6	18
87	RNA interference for improving the outcome of islet transplantation. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 47-68.	13.7	29
88	Extravasation of polymeric nanomedicines across tumor vasculature. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 623-639.	13.7	172
89	Target cell movement in cardiovascular and malignant diseases. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 555-557.	13.7	0
90	GFAP Promoter-Driven RNA Interference on TGF- β 1 to Treat Liver Fibrosis. <i>Pharmaceutical Research</i> , 2011, 28, 752-761.	3.5	18

#	ARTICLE	IF	CITATIONS
91	Mesenchymal Stem Cells as a Gene Delivery Vehicle for Successful Islet Transplantation. <i>Pharmaceutical Research</i> , 2011, 28, 2098-2109.	3.5	25
92	Subcellular Fate and Off-Target Effects of siRNA, shRNA, and miRNA. <i>Pharmaceutical Research</i> , 2011, 28, 2996-3015.	3.5	169
93	Biological and Therapeutic Applications of Small RNAs. <i>Pharmaceutical Research</i> , 2011, 28, 2961-2965.	3.5	9
94	Paclitaxel- and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer. <i>Drug Delivery and Translational Research</i> , 2011, 1, 420-428.	5.8	39
95	Poly(ethylene glycol)-Block-Poly(2-methyl-2-benzoxycarbonyl-propylene Carbonate) Micelles for Rapamycin Delivery: In Vitro Characterization and Biodistribution. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 2418-2429.	3.3	37
96	RGD peptide-modified adenovirus expressing hepatocyte growth factor and X-linked inhibitor of apoptosis improves islet transplantation. <i>Journal of Gene Medicine</i> , 2011, 13, 658-669.	2.8	17
97	Inhibition of Endogenous Hedgehog Signaling Protects Against Acute Liver Injury After Ischemia Reperfusion. <i>Pharmaceutical Research</i> , 2010, 27, 2492-2504.	3.5	26
98	Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100. <i>Journal of Controlled Release</i> , 2010, 143, 151-158.	9.9	30
99	Triplex forming oligonucleotides against type I collagen attenuates liver fibrosis induced by bile duct ligation. <i>Biochemical Pharmacology</i> , 2010, 80, 1718-1726.	4.4	16
100	Self-assembling methoxypoly(ethylene glycol)-b-poly(carbonate-co-l-lactide) block copolymers for drug delivery. <i>Biomaterials</i> , 2010, 31, 2358-2370.	11.4	90
101	Lipid and polymeric carrier-mediated nucleic acid delivery. <i>Expert Opinion on Drug Delivery</i> , 2010, 7, 1209-1226.	5.0	120
102	XIAP Gene Expression Protects β -Cells and Human Islets from Apoptotic Cell Death. <i>Molecular Pharmaceutics</i> , 2010, 7, 1655-1666.	4.6	25
103	Synthesis and Characterization of Amphiphilic Lipopolymers for Micellar Drug Delivery. <i>Biomacromolecules</i> , 2010, 11, 2610-2620.	5.4	112
104	Targeted Delivery of siRNA to Hepatocytes and Hepatic Stellate Cells by Bioconjugation. <i>Bioconjugate Chemistry</i> , 2010, 21, 2119-2127.	3.6	82
105	Gene expression and silencing for improved islet transplantation. <i>Journal of Controlled Release</i> , 2009, 140, 262-267.	9.9	17
106	Bipartite Adenoviral Vector Encoding hHGF and hIL-1Ra for Improved Human Islet Transplantation. <i>Pharmaceutical Research</i> , 2009, 26, 587-596.	3.5	23
107	Micellar Delivery of Bicalutamide and Embelin for Treating Prostate Cancer. <i>Pharmaceutical Research</i> , 2009, 26, 2081-92.	3.5	73
108	Hypoxia-specific gene expression for ischemic disease gene therapy. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 614-622.	13.7	47

#	ARTICLE	IF	CITATIONS
109	HPMA Polymer-Based Site-Specific Delivery of Oligonucleotides to Hepatic Stellate Cells. <i>Bioconjugate Chemistry</i> , 2009, 20, 213-221.	3.6	35
110	siRNA Delivery and Targeting. <i>Molecular Pharmaceutics</i> , 2009, 6, 649-650.	4.6	11
111	Bipartite Vector Encoding hVEGF and hIL-1Ra for ex Vivo Transduction into Human Islets. <i>Molecular Pharmaceutics</i> , 2009, 6, 274-284.	4.6	20
112	TGF- β 1 Gene Silencing for Treating Liver Fibrosis. <i>Molecular Pharmaceutics</i> , 2009, 6, 772-779.	4.6	92
113	RNAi for Treating Hepatitis B Viral Infection. <i>Pharmaceutical Research</i> , 2008, 25, 72-86.	3.5	112
114	Structural and Formulation Factors Influencing Pyridinium Lipid-Based Gene Transfer. <i>Bioconjugate Chemistry</i> , 2008, 19, 2499-2512.	3.6	41
115	Site-Specific Delivery of Oligonucleotides to Hepatocytes after Systemic Administration. <i>Bioconjugate Chemistry</i> , 2008, 19, 290-298.	3.6	39
116	Caspase-3 Gene Silencing for Inhibiting Apoptosis in Insulinoma Cells and Human Islets. <i>Molecular Pharmaceutics</i> , 2008, 5, 1093-1102.	4.6	36
117	iNOS Gene Silencing Prevents Inflammatory Cytokine-Induced β -Cell Apoptosis. <i>Molecular Pharmaceutics</i> , 2008, 5, 407-417.	4.6	30
118	siRNA pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection. <i>Journal of Drug Targeting</i> , 2008, 16, 140-148.	4.4	21
119	Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. <i>Rna</i> , 2007, 13, 431-456.	3.5	193
120	Coexpression of Vascular Endothelial Growth Factor and Interleukin-1 Receptor Antagonist for Improved Human Islet Survival and Function. <i>Molecular Pharmaceutics</i> , 2007, 4, 199-207.	4.6	17
121	Effect of iNOS and NF- κ B gene silencing on β -cell survival and function. <i>Journal of Drug Targeting</i> , 2007, 15, 358-369.	4.4	15
122	Gene Modulation for Treating Liver Fibrosis. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2007, 24, 93-146.	2.2	41
123	Receptor-Mediated Hepatic Uptake of M6P α -BSA-Conjugated Triplex-Forming Oligonucleotides in Rats. <i>Bioconjugate Chemistry</i> , 2006, 17, 823-830.	3.6	23
124	Biological and Biomaterial Approaches for Improved Islet Transplantation. <i>Pharmacological Reviews</i> , 2006, 58, 194-243.	16.0	171
125	Co-Expression of Vascular Endothelial Growth Factor and Interleukin-1 Receptor Antagonist Improves Human Islet Survival and Function. <i>Pharmaceutical Research</i> , 2006, 23, 1970-1982.	3.5	41
126	Enhanced Hepatic Uptake and Bioactivity of Type α 1(I) Collagen Gene Promoter-Specific Triplex-Forming Oligonucleotides after Conjugation with Cholesterol. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 797-805.	2.5	60

#	ARTICLE	IF	CITATIONS
127	Water insoluble and soluble lipids for gene delivery. <i>Advanced Drug Delivery Reviews</i> , 2005, 57, 699-712.	13.7	90
128	Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. <i>Expert Opinion on Drug Delivery</i> , 2005, 2, 3-28.	5.0	71
129	Biodistribution and Hepatic Uptake of Triplex-Forming Oligonucleotides against Type I (I) Collagen Gene Promoter in Normal and Fibrotic Rats. <i>Molecular Pharmaceutics</i> , 2005, 2, 206-217.	4.6	41
130	Cationic Lipids with Increased DNA Binding Affinity for Nonviral Gene Transfer in Dividing and Nondividing Cells. <i>Bioconjugate Chemistry</i> , 2005, 16, 156-168.	3.6	45
131	Targeted Delivery of a Triplex-Forming Oligonucleotide to Hepatic Stellate Cells. <i>Biochemistry</i> , 2005, 44, 4466-4476.	2.5	45
132	Vascular Endothelial Growth Factor Gene Delivery for Revascularization in Transplanted Human Islets. <i>Pharmaceutical Research</i> , 2004, 21, 15-25.	3.5	72
133	Cationic lipid and polymer-based gene delivery to human pancreatic islets. <i>Molecular Therapy</i> , 2003, 7, 89-100.	8.2	64
134	Novel Branched Poly(Ethylenimine)-Cholesterol Water-Soluble Lipopolymers for Gene Delivery. <i>Biomacromolecules</i> , 2002, 3, 1197-1207.	5.4	236
135	Optimization of factors influencing the transfection efficiency of folate-PEG-folate-graft-polyethylenimine. <i>Journal of Controlled Release</i> , 2002, 79, 255-269.	9.9	131
136	Novel water insoluble lipoparticulates for gene delivery. <i>Pharmaceutical Research</i> , 2002, 19, 382-390.	3.5	30
137	Water-Soluble Lipopolymer for Gene Delivery. <i>Bioconjugate Chemistry</i> , 2001, 12, 337-345.	3.6	205
138	Intratumoral Delivery of p2CMVml-12 Using Water-Soluble Lipopolymers. <i>Molecular Therapy</i> , 2001, 4, 130-138.	8.2	90
139	Folate-PEG-Folate-Graft-Polyethylenimine-Based Gene Delivery. <i>Journal of Drug Targeting</i> , 2001, 9, 123-139.	4.4	98
140	Soluble Biodegradable Polymer-Based Cytokine Gene Delivery for Cancer Treatment. <i>Molecular Therapy</i> , 2000, 2, 121-130.	8.2	94
141	pH-Sensitive Cationic Polymer Gene Delivery Vehicle: N-Ac-poly(L-histidine)-graft-poly(L-lysine) Comb Shaped Polymer. <i>Bioconjugate Chemistry</i> , 2000, 11, 637-645.	3.6	363
142	Development of Biomaterials for Gene Therapy. <i>Molecular Therapy</i> , 2000, 2, 302-317.	8.2	373
143	Pharmaceutical Perspectives of Nonviral Gene Therapy. <i>Advances in Genetics</i> , 1999, 41, 95-156.	1.8	126
144	Plasmid-Based Gene Therapy: Opportunities and Challenges Knock at the Millennium. <i>Journal of Drug Targeting</i> , 1999, 7, 241-243.	4.4	2

#	ARTICLE	IF	CITATIONS
145	Non-Viral Peptide-Based Approaches to Gene Delivery. <i>Journal of Drug Targeting</i> , 1999, 7, 249-268.	4.4	84
146	Extravasation of macromolecules. <i>Advanced Drug Delivery Reviews</i> , 1998, 34, 93-108.	13.7	122
147	Biodistribution and Gene Expression of Lipid/Plasmid Complexes after Systemic Administration. <i>Human Gene Therapy</i> , 1998, 9, 2083-2099.	2.7	160
148	Involvement of Specific Mechanism in Plasmid DNA Uptake by Mouse Peritoneal Macrophages. <i>Biochemical and Biophysical Research Communications</i> , 1998, 245, 729-733.	2.1	70
149	Development of Targeted Delivery Systems for Nucleic Acid Drugs. <i>Journal of Drug Targeting</i> , 1997, 4, 337-357.	4.4	53
150	Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine). <i>Biochemical Pharmacology</i> , 1997, 53, 887-895.	4.4	91
151	Cationic lipid-based gene delivery systems: pharmaceutical perspectives. <i>Pharmaceutical Research</i> , 1997, 14, 853-859.	3.5	200
152	Nonviral Vectors for In Vivo Gene Delivery: Physicochemical and Pharmacokinetic Considerations. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 1997, 14, 40.	2.2	101
153	Pharmacokinetics and targeted delivery of proteins and genes. <i>Journal of Controlled Release</i> , 1996, 41, 91-97.	9.9	51
154	Control of pharmacokinetic profiles of drug-macromolecule conjugates. <i>Advanced Drug Delivery Reviews</i> , 1996, 19, 377-399.	13.7	49
155	Disposition characteristics of plasmid DNA in the single-pass rat liver perfusion system. <i>Pharmaceutical Research</i> , 1996, 13, 599-603.	3.5	60
156	Uptake Characteristics of Oligonucleotides in the Isolated Rat Liver Perfusion System. <i>Oligonucleotides</i> , 1996, 6, 177-183.	4.3	32
157	Physicochemical and Pharmacokinetic Characteristics of Plasmid DNA/ Cationic Liposome Complexes. <i>Journal of Pharmaceutical Sciences</i> , 1995, 84, 1267-1271.	3.3	152
158	In Vivo Disposition Characteristics of Plasmid DNA Complexed with Cationic Liposomes. <i>Journal of Drug Targeting</i> , 1995, 3, 149-157.	4.4	108
159	Biopharmaceutical Challenges: Pulmonary Delivery of Proteins and Peptides. , 0, , 209-242.		1